NGM Biopharmaceuticals
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, NGM Biopharmaceuticals sits in the top decile of US sponsors by registered trial count (#801 of 15,742 sponsors by registered trial count).
NGM Biopharmaceuticals: 18 sponsored US clinical trials, 1 recruiting.
NGM Biopharmaceuticals sponsors 18 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 14 completed. 0 of these trials are in Phase 3-4 (later-stage) and 18 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Squamous Cell Carcinoma of Head and Neck, with 3 trials.
Top-decile sponsor footprint
NGM Biopharmaceuticals ranks in the top decile of sponsors by registered trial count (#801 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
14 of 14 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
18 total, page 1 of 1
An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.
NCT07033026
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NCT05311618
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
NCT05215574
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
NCT04913337
Study of Aldafermin (NGM282) in Healthy Adult Male Japanese and Non-Japanese Subjects
NCT04828265
Study of Aldafermin (NGM282) in Participants With Impaired Hepatic Function
NCT04823702
A Study of NGM621 in Participants With Geographic Atrophy
NCT04465955
Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4)
NCT04210245
Study of Aldafermin (NGM282) in Participants With Impaired Renal Function
NCT04179630
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
NCT04068896
Study of NGM621 in Participants With Geographic Atrophy
NCT04014777
Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3)
NCT03912532
Study of NGM313 in Obese Participants
NCT03298464
A Study of NGM282 in Patients With Primary Sclerosing Cholangitis
NCT02704364
Study of NGM282 in Subjects With Functional Constipation and Healthy Individuals
NCT02649062
Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)
NCT02443116
Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis
NCT02135536
Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis
NCT02026401
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 10 |
| Phase 2 | 8 |
What is open in the NGM Biopharmaceuticals pipeline
1 recruiting of 18 indexed (6% open); 14 completed (78%).
Phase mix: 0 late (III/IV) vs 18 early (I/II) (early-phase heavy).
Top condition: Squamous Cell Carcinoma of Head and Neck (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
NGM Biopharmaceuticals: open-pipeline peers nationwide
Peers matched on 18 registered trials and 6% open enrollment, not the therapeutic-area sidebar.
NGM Biopharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 18 trials (± recruiting share)
- ADC Therapeutics S.A. · 18 trials · 11% recruiting
- Akros Pharma · 18 trials · 0% recruiting
- AO Clinical Investigation and Publishing Documentation · 18 trials · 0% recruiting
- AO Innovation Translation Center · 18 trials · 33% recruiting
Sponsors near 6% open enrollment (± trial volume)
- Boston College · 6% recruiting · 18 trials
- CytoDyn · 6% recruiting · 18 trials
- Dendreon · 6% recruiting · 18 trials
- Intercept Pharmaceuticals · 6% recruiting · 18 trials
Related
What to do with this NGM Biopharmaceuticals page
18 registered trials is a research-attention snapshot, not an endorsement of NGM Biopharmaceuticals or any single study.
- 1 of NGM Biopharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Squamous Cell Carcinoma of Head and Neck is the condition NGM Biopharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Squamous Cell Carcinoma of Head and Neck trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
NGM Biopharmaceuticals pipeline card: 18 registered trials from official public datasets.Report a data error.